

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification by entering the Substitute Sequence Listing submitted concurrently herewith in paper and computer-readable format (CRF).

Please amend paragraph [0038] at page 7 of the specification as follows:

[0038] ~~FIGURE 11 depicts~~ FIGURES 11A-1, 11A-2, 11B-1, 11B-2, 11C-1, 11C-2, 11D-1, and 11D-2 depict the sequences of the light chain variable regions (VK) for humanization of monoclonal antibody 228B/C-1. Clones B to R represent clones tested with a human template 2 for VK and a murine VH. HT2-NEW and HT2-DP27 clones were constructed with human frameworks for both VK and VH. The amino acid sequences of framework region (FR) 1 (Figures 11A-1 and 11C-1), FR2 (Figures 11A-2 and 11C-2), FR3 (Figures 11B-1 and 11D-1), and FR4 (Figures 11B-2 and 11D-2) of the VK of the indicated clones are depicted.

Please amend paragraph [0039] at page 7 of the specification as follows:

[0039] ~~FIGURE 12 depicts~~ FIGURES 12A-1, 12A-2, 12B-1, 12B-2, 12C-1, 12C-2, 12C-3, 12C-4, 12D-1, 12D-2, 12D-3, and 12D-4 depict the corresponding heavy chain variable region sequences of clones in Figure 11 (i.e., 11A-1, 11A-1, 11B-1, 11B-2, 11C-1, 11C-2, 11D-1, and 11D-2). The amino acid sequences of FR1 (Figures 12A-1, 12C-1, and 12C-2), FR2 (Figures 12A-2, 12C-3, and 12C-4), FR3 (Figures 12B-1, 12D-1 and 12D-2), and FR4 (Figures 12B-2, 12D-3 and 12D-4) of the VH of the indicated clones are depicted.

Please amend paragraph [0040] at page 7 of the specification as follows:

[0040] ~~FIGURE 13 [[A-E]]A-D depict ELISA profiles for combinatorial humanized candidates.~~

Please amend paragraph [0045] at page 7 of the specification as follows:

[0045] Figure 18 shows the alignment of IL13 protein sequences. The amino acid sequence for the following species of IL-13 protein are aligned: human (SEQ ID NO: 187), monkey (SEQ ID NO: 188), bovine (SEQ ID NO: 189), dog (SEQ ID NO: 190), rat (SEQ ID

NO: 191), mouse (SEQ ID NO: 192), and gerbil (SEQ ID NO: 193). The majority sequence (SEQ ID NO: 186) based on the alignment is depicted.

Please amend paragraph [0046] at page 7 of the specification as follows:

[0046] Figure 19 depicts the binding epitope of Mab 228B/C-1. The human (SEQ ID NO: 187), monkey (SEQ ID NO: 188) and mouse (SEQ ID NO: 192) IL-13 amino acid sequences are depicted.

Please amend paragraph [0048] at page 7 of the specification as follows:

[0048] Figure 21 depicts Figures 21A and 21B depict the variable light chain and variable heavy chain sequences for select candidate recombinant antibodies.

Please amend paragraph [00218] starting at page 43 of the specification as follows:

[00218] These combinations were tested by ELISA to determine if there was any further loss of function upon further humanization. For these assays, the antigen IL-13 was captured on the plate in a limiting amount. The anti-IL13 Fabs were then added to the plate at a known concentration and titrated down the plate at a 1:3 dilution. Binding was detected with a secondary antibody that is specific for Fab. Fig. 13 depicts the functional assay results. Fig. 13A - 115Vk/73Vh; Fig. 13B- 89Vk/276Vh; Fig. 13C -144Vk/276Vh; and Fig. 13D -144Vk/123Vh; and Fig. 13E - 144Vk/73Vh. From these data, the observed results suggested that the engineered combinations of humanized variable regions did not adversely affect the binding of the Fabs to the antigen.